Trial Profile
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalacom combination ophthalmic solution.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2021
Price :
$35
*
At a glance
- Drugs Carteolol/latanoprost (Primary) ; Latanoprost/timolol
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions; Therapeutic Use
- 24 Aug 2020 Planned End Date changed from 19 Jun 2019 to 16 Mar 2020.
- 22 Feb 2017 New trial record